Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
| 2.61 | |
| 2.62 | |
| - | |
| 2.64 | |
| 2.54 | |
| 1.46-3.26 | |
| 379 M | |
| 148 M | |
| 171 M | |
| -0.14 | |
| 1.294 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
2023 was dominated by the Magnificent Seven stocks, which has left investors wondering how much higher mega-cap stocks can go. Investors worry that growth is nearing a peak or perhaps reversing. That ...
In this article, we discuss 11 high-growth micro-cap stocks to buy. To skip the detailed analysis and past performance of micro-cap stocks, go directly to the 5 High Growth Micro-cap Stocks to Buy. S...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
